Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
John G F Cleland,Philip A Kalra,Pierpaolo Pellicori,Fraser J Graham,Paul W X Foley,Iain B Squire,Peter J Cowburn,Alison Seed,Andrew L Clark,Ben Szwejkowski,Prithwish Banerjee,Justin Cooke,Mark Francis,Piers Clifford,Aaron Wong,Colin Petrie,John J V McMurray,Elizabeth A Thomson,Kirsty Wetherall,Michele Robertson,Ian Ford,Paul R Kalra,Paul Kalra,Elena Cowan,Charlotte Turner,Rosalynn Austin,Rebeca Lane,Paula Rogers,Paul Foley,Badri Chandrasekaran,Eva Fraile,Lynsey Kyeremeh,Fozia Ahmed,Mark Petrie,Lorraine McGregor,Joanna Osmanska,Fraser Graham,Ninian Lang,Barbara Meyer,Faheem Ahmad,Joanna Osmanska,Iain Squire,Jude Fisher,Philip Kalra,Christina Summersgill,Katarzyna Adeniji,Rajkumar Chinnadurai,Andrew Ludman,Lisa Massimo,Clare Hardman,Daisy Sykes,Peter Cowburn,Sarah Frank,Simon Smith,Alan Japp,Mohamed Anwar,Beth Whittington,Alison Seed,Robin Ray,Vennessa Sookhoo,Sinead Lyons,Abdallah Al-Mohammad,Janet Middle,Kay Housley,Andrew Clark,Jeanne Bulemfu,Christopher Critoph,Victor Chong,Stephen Wood,Benjamin Szwejkowski,Chim Lang,Jackie Duff,Susan MacDonald,Rebekah Schiff,Patrick Donnelly,Thuraia Nageh,Swapna Kunhunny,Mark Petrie,Roy Gardner,Marion McAdam,Elizabeth McPherson,Prithwish Banerjee,Eleanor Sear,Nigel Edwards,Jason Glover,Pierpaolo Pellicori,Clare Murphy,Justin Cooke,Charles Spencer,Mark Francis,Iain Matthews,Hayley McKie,Andrew Marshall,Janet Large,Jenny Stratford,Piers Clifford,Christopher Boos,Philip Keeling,Aaron Wong,Deborah Jones,Alex James,Rhys Williams,Stephen Leslie,Jim Finlayson,Piers Clifford,Andrew Hannah,Philip Campbell,John Walsh,Jane Quinn,Callum Chapman,Susan Piper,Sheetal Patale,Preeti Gupta,Victor Sim,Lucy Knibbs,Kristopher Lyons,Lana Dixon,Colin Petrie,Yuk-ki Wong,Catherine Labinjoh,Simon Duckett,Ian Massey,Henry Savage,Sofia Matias,Jonaifah Ramirez,Charlotte Manisty,Ifza Hussain,Rajiv Sankaranarayanan,Gershan Davis,Samuel McClure,John Baxter,Eleanor Wicks,Jolanta Sobolewska,Jerry Murphy,Ahmed Elzayat,Jay Wright,Simon Williams,Amal Muthumala,Parminder Chaggar,Sue Webber,Gethin Ellis,Mandie Welch,Sudantha Bulugahapitiya,Thomas Jackson,Tapesh Pakrashi,Ameet Bakhai,Vinodh Krishnamurthy,Reto Gamma,Susan Ellery,Charlotte Manisty,Geraint Jenkins,Angus Nightingale,Elizabeth Thomson,Ian Ford,Michele Robertson,Nicola Greenlaw,Kirsty Wetherall,Ross Clarke,Christopher Graham,Sharon Kean,Alan Stevenson,Robbie Wilson,Sarah Boyle,John McHugh,Lisa Hall,Joanne Woollard,Claire Brunton,Eleanor Dinnett,Amanda Reid,Serena Howe,Jill Nicholls,Anna Cunnington,Elizabeth Douglas,Margaret Fegen,Marc Jones,Sheila McGowan,Barbara Ross,Pamela Sandu,Pamela Surtees,Debra Stuart,Nicholas Boon,Shannon Amoils,Callum Chapman,John Cleland,Thomas Goldin Diness,Ian Ford,Paul Kalra,Philip Kalra,Iain Macdougall,John McMurray,Richard Mindham,Mark Petrie,Pamela Sandu,Iain Squire,Claes Christian Strom,Elizabeth Thomson,Maureen Travers,Robert Wilcox,Allan Struthers,Patrick Mark,Christopher Weir,John Cleland,Fraser Graham,Pierpaolo Pellicori,the IRONMAN Study Group
DOI: https://doi.org/10.1093/eurheartj/ehae086
IF: 39.3
2024-03-07
European Heart Journal
Abstract:Background and Aims What is the relationship between blood tests for iron deficiency, including anaemia, and the response to intravenous iron in patients with heart failure? Methods In the IRONMAN trial, 1137 patients with heart failure, ejection fraction ≤ 45%, and either serum ferritin < 100 μg/L or transferrin saturation (TSAT) < 20% were randomized to intravenous ferric derisomaltose (FDI) or usual care. Relationships were investigated between baseline anaemia severity, ferritin and TSAT, to changes in haemoglobin from baseline to 4 months, Minnesota Living with Heart Failure (MLwHF) score and 6-minute walk distance achieved at 4 months, and clinical events, including heart failure hospitalization (recurrent) or cardiovascular death. Results The rise in haemoglobin after administering FDI, adjusted for usual care, was greater for lower baseline TSAT (Pinteraction < .0001) and ferritin (Pinteraction = .028) and more severe anaemia (Pinteraction = .014). MLwHF scores at 4 months were somewhat lower (better) with FDI for more anaemic patients (overall Pinteraction = .14; physical Pinteraction = .085; emotional Pinteraction = .043) but were not related to baseline TSAT or ferritin. Blood tests did not predict difference in achieved walking distance for those randomized to FDI compared to control. The absence of anaemia or a TSAT ≥ 20% was associated with lower event rates and little evidence of benefit from FDI. More severe anaemia or TSAT < 20%, especially when ferritin was ≥100 μg/L, was associated with higher event rates and greater absolute reductions in events with FDI, albeit not statistically significant. Conclusions This hypothesis-generating analysis suggests that anaemia or TSAT 100 μg/L might identify patients with heart failure who obtain greater benefit from intravenous iron. This interpretation requires confirmation.
cardiac & cardiovascular systems